[5-Ethyl-2-(1-hydroxypentan-3-yloxy)phenyl]-phenylmethanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [5-Ethyl-2-(1-hydroxypentan-3-yloxy)phenyl]-phenylmethanone
• 英文别名: [5-ethyl-2-(1-hydroxypentan-3-yloxy)phenyl]-phenylmethanone
• 化学式: C₂₀H₂₄O₃
• 分子量: 312.409
• InChiKey: BWWUXVLPVXXPSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [5-Ethyl-2-(1-hydroxypentan-3-yloxy)phenyl]-phenylmethanone 在 caesium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c
• 作为产物：
  描述：

  戊烷-1,3-二醇 在 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 [5-Ethyl-2-(1-hydroxypentan-3-yloxy)phenyl]-phenylmethanone
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c

文献信息

• Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile
  作者：Yanping Xu、Garret J. Etgen、Carol L. Broderick、Emily Canada、Isabel Gonzalez、Jason Lamar、Chahrzad Montrose-Rafizadeh、Brian A. Oldham、John J. Osborne、Chaoyu Xie、Qing Shi、Leonard L. Winneroski、Jeremy York、Nathan Yumibe、Richard Zink、Nathan Mantlo

  DOI：10.1021/jm060617c

  日期：2006.9.1

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.